You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines
SBC: TENDEL THERAPIES INC Topic: NIAIDThis grant is for translational development of a scalable, nucleic acid-based formulation of cytomegalovirus-vectored vaccines that can be distributed without a cold chain. HIV candidate vaccines that use cytomegalovirus (CMV) as delivery vector and immunomodulatory adjuvant have shown extraordinary promise. In our preliminary work, for example, a rhesus cytomegalovirus-vectored SIV vaccine lackin ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
improving Cas9 mediated homologous recombination in pluripotent stem cells
SBC: APPLIED STEMCELL, INC. Topic: 200DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Vaccine for Acute Flaccid Myelitis
SBC: ALEPH THERAPEUTICS INC Topic: NIAIDSUMMARYIn 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinical, immunological, and epidemiological evidence has pointed to EV-D68 as the major causative agent of ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Q-GRFT Enema Development Supporting a Multi-Administration Clinical Study
SBC: GROW BIOMEDICINE LLC Topic: NIAIDProject Summary Unprotected receptive anal intercourse (RAI) is the sexual behavior with the highest per-act risk of HIV acquisition, conferring 10 to 20 times more risk than unprotected vaginal intercourse. We are developing an antiviral rectal rinse (enema) using a novel HIV entry inhibitor, the lectin Griffithsin (GRFT), because there is a lack of on-demand antiviral HIV prevention products tha ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
SBC: Molecular Express Inc Topic: R42DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a Gene and Oligonucleotide Delivery System
SBC: Molecular Express Inc Topic: NCATSDESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
SBC: Molecular Express Inc Topic: R42DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Developing novel RPPA for the detection of metastatic prostate cancer
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 400PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: NIAPROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health